Needham Investment Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-180,000
| Closed | -$410K | – | 151 |
|
|
2024
Q2 | $410K | Hold |
180,000
| – | – | 0.03% | 136 |
|
|
2024
Q1 | $778K | Hold |
180,000
| – | – | 0.07% | 119 |
|
|
2023
Q4 | $549K | Sell |
180,000
-54,000
| -23% | -$101K | 0.07% | 119 |
|
|
2023
Q3 | $337K | Hold |
234,000
| – | – | 0.06% | 113 |
|
|
2023
Q2 | $583K | Hold |
234,000
| – | – | 0.1% | 100 |
|
|
2023
Q1 | $627K | Buy |
234,000
+50,000
| +27% | +$240K | 0.11% | 103 |
|
|
2022
Q4 | $999K | Buy |
184,000
+50,000
| +37% | +$419K | 0.18% | 89 |
|
|
2022
Q3 | $1.67M | Hold |
134,000
| – | – | 0.33% | 66 |
|
|
2022
Q2 | $662K | Sell |
134,000
-26,000
| -16% | -$144K | 0.12% | 103 |
|
|
2022
Q1 | $1.22M | Buy |
160,000
+45,000
| +39% | +$427K | 0.18% | 88 |
|
|
2021
Q4 | $1.17M | Buy |
115,000
+26,500
| +30% | +$338K | 0.15% | 86 |
|
|
2021
Q3 | $1.19M | Buy |
88,500
+61,000
| +222% | +$994K | 0.16% | 83 |
|
|
2021
Q2 | $603K | Buy |
27,500
+7,500
| +38% | +$167K | 0.09% | 102 |
|
|
2021
Q1 | $481K | Buy |
20,000
+2,000
| +11% | +$46.5K | 0.07% | 109 |
|
|
2020
Q4 | $324K | Buy |
+18,000
| New | +$269K | 0.05% | 105 |
|
Needham Investment Management's GTHX Position: Q3 2024 in Review
Needham Investment Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 180,000 shares — an estimated $410K sold.
Needham Investment Management first reported a position in GTHX in Q4 2020 and held it in 15 quarters. The position peaked at $1.67M in Q3 2022. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Needham Investment Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Needham Investment Management sold 180,000 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $410K.
- Needham Investment Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
- Needham Investment Management's G1 Therapeutics, Inc. Common Stock position peaked at $1.67M in Q3 2022.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Needham Investment Management's 13F filing for Q3 2024, filed 14 Nov 2024.